Evaluation of Sinusitis

Aetna considers detection of IgG4-positive plasma cells in the nasal/paranasal sinuses; tissue eosinophilia assessment for predicting CRS severity or CRS‑associated olfactory loss; evaluation of tissue EGFR ligands (e.g., epiregulin) and matrix metalloproteinases; and microarray DNA testing for chronic rhinosinusitis to be experimental/investigational and therefore not covered. These services are excluded because there is insufficient evidence to support their clinical utility.

"This Clinical Policy Bulletin addresses the evaluation of sinusitis."

Sign up to see full coverage criteria, indications, and limitations.